NCT07232758

Safety, Tolerability and Pharmacokinetic Studies of HRS-2183 for Injection in Healthy Chinese Subjects After Single and Multiple Administration

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study mainly evaluated the safety and tolerability, as well as the pharmacokinetic characteristics, of the injectable drug HRS-2183 after single and multiple administrations in healthy subjects.

Conditions

• Chinese Healthy Adult Subjects

Interventions

Type	Name	Description
DRUG	HRS-2183	HRS-2183
DRUG	Placebo	placebo

Timeline

• Start date: 2025-10-30
• Primary completion: 2026-02-01
• Completion: 2026-02-01
• First posted: 2025-11-18
• Last updated: 2025-11-18

Locations

1 site across 1 country: China